{"id":"budipine","rwe":[],"tags":[{"label":"budipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily H member 2","category":"target"},{"label":"KCNH2","category":"gene"},{"label":"GRIN1","category":"gene"},{"label":"GRIN2A","category":"gene"},{"label":"N04BX03","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["budipine"],"offLabel":[],"synonyms":["budipine"],"timeline":[],"aiSummary":"Budipine is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a budipine drug and its mechanism of action is not FDA approved for any indications. The commercial status of budipine is unknown, and it is not clear if it is patented or available as a generic. Further research is needed to determine its safety and efficacy. Budipine's pharmacokinetic properties, including half-life and bioavailability, are also unknown.","ecosystem":[],"mechanism":{"target":"Potassium voltage-gated channel subfamily H member 2, Glutamate [NMDA] receptor","targets":[{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"GRIN1","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 1"},{"gene":"GRIN2A","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 2A"},{"gene":"GRIN2B","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 2B"},{"gene":"GRIN2C","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 2C"},{"gene":"GRIN2D","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 2D"},{"gene":"GRIN3A","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 3A"},{"gene":"GRIN3B","source":"DrugCentral","target":"Glutamate [NMDA] receptor","protein":"Glutamate receptor ionotropic, NMDA 3B"}],"modality":"Small Molecule","drugClass":"budipine","explanation":"Think of your brain's electrical activity like a stormy ocean. Potassium channels help calm the waves, but in some cases, these channels can get overactive and cause problems. Budipine helps block these channels, reducing the stormy activity and potentially treating certain conditions.","oneSentence":"Budipine works by blocking potassium channels in the brain, which can help regulate abnormal electrical activity.","technicalDetail":"Budipine acts as a selective blocker of the Kv11.1 potassium channel, which is involved in the regulation of cardiac and neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/420","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:04:35.300383","biosimilars":[],"competitors":[{"drugName":"tolcapone","drugSlug":"tolcapone","fdaApproval":"1998-01-29","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"entacapone","drugSlug":"entacapone","fdaApproval":"1999-10-19","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"opicapone","drugSlug":"opicapone","fdaApproval":"2020-04-24","patentExpiry":"Oct 10, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"budipine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tolcapone","brandName":"tolcapone","genericName":"tolcapone","approvalYear":"1998","relationship":"same-class"},{"drugId":"entacapone","brandName":"entacapone","genericName":"entacapone","approvalYear":"1999","relationship":"same-class"},{"drugId":"opicapone","brandName":"opicapone","genericName":"opicapone","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"007104","UNII":"L9026OPI2Z","INN_ID":"4037","RXNORM":"19832","UMLSCUI":"C0054202","ChEMBL_ID":"CHEMBL334491","KEGG_DRUG":"D07306","DRUGBANK_ID":"DB13502","PUBCHEM_CID":"68778","MESH_SUPPLEMENTAL_RECORD_UI":"C026710"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"47%"},"publicationCount":64,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N04BX03","allCodes":["N04BX03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"BUDIPINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}